Windtree Therapeutics Inc (WINT) Quote

Windtree Announces Transformational Agreement to Acquire Revenue Generating Environmental Services Business
Windtree continues its transformation entering the rapidly growing $85 billion US environmental services space

Refocused strategy is expected to generate $12 million in revenue over the next 12 months

Transaction expected to produce a profitable business with growth opportunities through a roll up strategy

Windtree continues to pursue partnership or sale of pharmaceutical assets to reduce costs

WARRINGTON, Pa., June 10, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a diversified company focused on revenue generation in multiple growing industries, today announced a significant step in its drive toward overall profitability through its entry into a binding agreement to acquire Titan Environmental Services, Inc. (“Titan”)(OTC: TESI), a waste management business with operations in Michigan.

As consideration for the transaction, Windtree will issue preferred shares and has secured debt financing to fund the transaction and working capital for the business. Titan Environmental Services will become Windtree Environmental Services (“Windtree Environmental”) and operate as a subsidiary of Windtree. Members of Titan’s current management team will be retained to leverage their extensive experience in the waste management industry. The transaction is expected to close in the 3rd quarter. In the event an agreement cannot be consummated, the Company is entitled to an $8.0 million breakup fee.

Over the last several months, Titan has undergone changes to its management and strategy, eliminating non-core assets, in order to focus on its waste management expertise to drive revenue. The United States waste collection market was valued at $85 billion in 2024 and has historically generated attractive EBITDA margins and free cash flow. In addition to the acquisition of Titan, the Company believes the fragmented waste management market may provide an opportunity to scale the business and provide additional top-line revenue growth and positive EBITDA contributions through additional acquisitions. Windtree Environmental intends to immediately begin the implementation and execution of a roll-up strategy to capitalize on this opportunity.

Under Windtree’s refined corporate strategy, the Company has, and continues to, pursue opportunities in a multitude of growing industries to drive toward overall profitability. The Company continues to evaluate options for its drug candidate pipeline in an effort to reduce costs and increase overall profitability.

“This transaction strategically aligns with our vision of diversifying our business model by increasing revenue and providing significant growth potential for the Company,” said Jed Latkin, Chief Executive Officer of Windtree. “We look forward to working with the Titan management and continuing to execute on our refined corporate strategy.”

About Windtree Therapeutics, Inc.
Windtree Therapeutics, Inc. is a diversified company focused on becoming a revenue-generating company in a multitude of growing industries to drive toward overall profitability.

WINT..............................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783

WINT, 10Q due Thursday 4/17

Did somebody mention rveginas ?

$WINT: Who doesn't love Vaginal News

Am I right Ladies ???


GO $WINT

WINT...................................................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783

Vaginal news followed up by compliance news this morning  $3.55 + 40% . Be wise low float 800k but offering comes eventually 

WINT.......................................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783

Power hour...wint at 2.16...will it get pumped at eod??

$WINT: We're going to $5 before EOD

You heard it here first....................... Don't be scared now


GO $WINT

$WINT; $3.40 babyyyyyyyyyyyyyyyyyyyyyyyyy

Whos havin a good time............ talk to me now


GO $WINT

$WINT: Bring on the $3 breaker baby


You know you wannnnaaaaaaaaaaaaaaaaaaaaaaaa

Do it for DADDY


GO $WINT

$WINT: Now 2.70 ....................

Holla back if you making money off my CALLOUTS !!!!!!!!!!!!!!!

Love to hear from you.

Keep on ROcking in the Free World............ while its still a Free World




GO $WINT

WINT.........................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783

$WINT: Going on News...............




GO $WINT

$WINT: The bottom is in............ look at 200day chart

Shes gonna get to $3 today

GO $WINT

$WINT: BOoommmmmmmmmmmm.... now $2.20

Thar she blowwwwwwwwwssssssssssssss


GO $WINT

WINT........................................................................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783

WINT EXPLOSION

WINT POST SPLIT MOVE

WINT, new 52 week low

RS info -1 for 50- feb 20--Windtree Therapeutics, Inc. (NasdaqCM: WINT) (“Windtree” or the “Company”), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, announces that its board of directors has approved a 1-for-50 reverse stock split of the Company’s common stock. The Company’s stockholders approved the reverse stock split proposal at the Company’s Special Meeting of Stockholders held on February 3, 2025. The stockholders granted the board of directors the authority to determine the exact split ratio and when to proceed with the reverse stock split.
The reverse stock split will become effective on February 20, 2025 at 5:00 p.m., Eastern Time (the “Effective Time”), and the Company’s common stock is expected to begin trading on a reverse stock split-adjusted basis on The Nasdaq Capital Market (“Nasdaq”) on February 21, 2025 at market open under the existing ticker symbol, “WINT.” The reverse stock split is intended to increase the price per share of the Company’s common stock to allow the Company to demonstrate compliance with the $1.00 minimum bid price requirement for continued listing on Nasdaq, among other benefits.

big uptick on GNS also 😅

nice move 😁

WINT.............................................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783

.2530 + 58%

Jumped in today .125 heavy

great site- thanks RS 5 to 50 Vote Approved

Scroll 9 down...https://dilutiontracker.com/app/reverse-split

RS approved- no ratio announced yet

$WINT Hmm reversal here starting? Maybe run before 2/3 meeting.

checked for reason on surge and nothing visible, even on website

today announced that Alexandre Mebazaa, MD, one of the world’s recognized leaders in cardiogenic shock, gave a well-received presentation highlighting the data on istaroxime from the recently completed Phase 2b SEISMiC B study in early cardiogenic shock due to heart failure. The presentation was given at the Cardiovascular Clinical Trials Conference in Washington, DC.

Dr. Alexandre Mebazaa is Professor of Medicine at Université Paris Cité (France), Chair of Department of Anesthesia & Critical Care and an expert in heart failure and cardiogenic shock. He is part of the task force that wrote the 2021 ESC/HFA Guidelines of Heart Failure and the 2023 addendum.

WINT, new 52 low

WINT 10Q due 11/11

Took another position here, this could very easily be a $30.00 stock in 2 years, patience pays.

Ping pong .80s to $1s

This may be the bottom for a longer term play,if they are successful with phase three it will be a $30.00 +/- stock. IMO

WINT.....................................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783

WINT take smaller gain .94s to $1.20 exit having trouble on bigger breakout to $1.40s

1.11 test again

WINT $1.11 breakout solid and $1.44
Up next 3m floater

Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the issuance of an istaroxime patent for Japan. The patent is entitled, “Istaroxime-containing intravenous formulation for the treatment of heart failure (AHF).” The claims are directed to intravenous administration of istaroxime using increased infusion times alone or in combination with other agents useful to treat AHF, thereby improving treatment of heart failure and diastolic relaxation when compared to conventional protocols. The application has been accorded Patent No. 7560134 with a registration date of September 24, 2024 and will expire in 2039.

WINT new 52 week low

WINT new 52=week low

Yup they pr only to dilute there share pos?? Imo

Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the trial design of its SEISMiC Phase 2b has been published by the European Society of Cardiology Heart Failure. The article is entitled, “Safety and efficacy of up to 60 hours of intravenous istaroxime in pre-cardiogenic shock patients: Design of the SEISMiC trial.” It can be found online in Wiley Online Library DIO: 10.1002/ehf2.15102. Results can be viewed at https://ir.windtreetx.com/corporate-presentation. The Heart Failure Society of America also shared the results.

$1.26 + 36%

Pump it

WINT anew 52 week low